A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer
Condition(s):Prostate Cancer; Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)Last Updated:November 20, 2015Withdrawn
Hide Studies Not Open or Pending
Condition(s):Prostate Cancer; Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)Last Updated:November 20, 2015Withdrawn
Condition(s):Multiple MyelomaLast Updated:November 18, 2023Recruiting
Condition(s):Prostate CancerLast Updated:October 21, 2015Completed
Condition(s):Prostatic Neoplasms, Castration-ResistantLast Updated:April 23, 2021Terminated
Condition(s):HealthyLast Updated:August 27, 2014Completed
Condition(s):Prostate CancerLast Updated:September 4, 2018Completed
Condition(s):Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate CancerLast Updated:April 27, 2023Completed
Condition(s):Metastatic Castrate Resistant Prostate CancerLast Updated:November 22, 2019Terminated
Condition(s):Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-Essential Thrombocytosis MyelofibrosisLast Updated:March 25, 2024Not yet recruiting
Condition(s):Advanced or Metastatic Hepatocellular Cancer; Advanced or Metastatic Ovarian Cancer; Metastatic Renal Cell Cancer; Advanced or Metastatic Gastric CarcinomaLast Updated:January 8, 2019Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.